Use of mycelial waste from the drug industry

It was shown that mycelial waste (MW) from manufacture of riboxin and neomycin was useful as an active filler for press compositions and a raw material for fuels. Addition of MW to a polymer press composition, depending on the amount added, provided a 2-10-fold decrease in the time of gel formation in the mixture and hardening of the products as well as a significant decrease in their shrinkage during the hardening. Optimal physicomechanical properties were achieved when the contents of MW and polymer in the press composition were equal. Pyrolysis of dry MW at a temperature of 450-500 degrees C resulted in formation of a product which was not inferior to the known fuels in its physicochemical properties. The low freezing point of the prepared fuel as compared to that of oil fuels allowed one to recommend it as a low-temperature additive to the fuels lowering their freezing points.     

The role of modern biology and medicine in drug development in academia and industry

This symposium addresses careers in drug development in industry; the performance of translational research by academia, industry, and both; and numerous factors pertinent to alliances essential to drug discovery and development. Drug development is a complex process that regularly involves effective collaborations between academic and physician scientists and industry. There are specific occupational factors affecting recruitment of scientists and physicians in drug development programs in industry; ideal backgrounds for successful applicants for positions in industry in drug development; ethical and regulatory considerations particularly germane to the performance of scientists and physicians in drug development programs in industry and at universities; and particular gratifications available to scientists in industry working on drug development. Both similarities and differences characterize the performance of translational research in industry compared with academia. In industry, logistic, operational, and scientific oversight is complex, especially because it often involves relationships with clinical enterprises outside of the corporation. The process is long and arduous from formulation of a good idea in discovery to acceptance of a novel drug in the marketplace. Collaborations and partnerships by industry often involving academia and confrontation of multiple issues are pivotal.